Cipla Limited, the Indian pharmaceutical major headquartered in Mumbai has reported its earnings for the quarter that ended on 31st March 2023, the Indian pharma giant has registered a rise of 8.3 per cent in its consolidated revenue to be recorded at Rs 5,739 crores in the Quarter Four of Financial Year 2022(Q4FY23) up from Rs 5,260 crores in the corresponding quarter last year.
Whereas the pharma company recorded a 1.2 per cent dip in its revenues compared with the previous quarter (Q3FY23) where the company posted revenue of Rs 5,810 crores.
The pharmaceutical company’s consolidated revenue for the financial year 2023 stood at Rs 22,753 crores, a rise of 4.3 per cent when compared with the revenues of last year which stood at Rs 21,763 crores.
The pharmaceutical company’s net profit jumped by 40 per cent year on year (YoY) in Q4FY23, the company recorded a net profit of Rs 521 crores in the March quarter. The company saw an increase of Rs 151 crores from the earnings of the same quarter last year which stood at Rs 370 crores.
The company’s net profit for FY23 came in at Rs 2,832 crores against Rs 2,546 crores in FY22, a jump of 11.2 per cent year on year.